

# EU medicines agency suspends Zinbryta

March 7 2018

---

The London-based European Medicines Agency announced Wednesday that multiple sclerosis drug Zinbryta has been suspended immediately and recalled due to reports that it sparked brain inflammation.

The decision followed 12 reports of serious inflammatory brain disorders worldwide including encephalitis and meningoencephalitis, the EMA said, adding that three of the cases were fatal.

"The EMA has recommended the immediate suspension and recall of the multiple sclerosis medicine Zinbryta," the body said in a statement.

Back in November, Amsterdam won a fierce fight to host the EMA after it leaves London, securing one of the most prized spoils of Britain's decision to leave the EU.

© 2018 AFP

Citation: EU medicines agency suspends Zinbryta (2018, March 7) retrieved 27 April 2024 from <https://medicalxpress.com/news/2018-03-eu-medicines-agency-zinbryta.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------